Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Lynx Reports Increased Revenue, Narrowed Loss in Q1

NEW YORK, May 2 - Lynx Therapeutics today reported a strong increase in first-quarter revenues and a narrowed net loss.

 

Total revenue for the period ended March 31 was $5.0 million, a 48 percent increase from the $3.4 million it reported one year ago.

 

Total operating expenses in the quarter grew slightly to $9 million from $8.6 million. This was led chiefly by mild growth in R&D spending, which came to $6.9 million from $6.0 million in the year-ago period.

 

Net loss was roughly $3.8 million, or $.27 per share, in the current first quarter compared with $5.7 million, or $.50 per share, year over year, Lynx reported.

 

The company had total cash, cash equivalents, and short-term investments of just under $2 million as of March 31.

 

Click here for more information.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.